[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-pancreatic-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,77,105,133,155,182,203,227,248,268,288,310],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100537486","phase-1-safety-and-efficacy-of-nrt6008-in-patients-with-unresectable-locally-advanced-pancreatic-cancer-lapc-and-advanced-pancreatic-cancer-with-lymph-node-metastases-100537486",false,"NCT06278454","Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases","A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of NRT6008 Injection in Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases","Inclusion Criteria:\n\n1. Aged ≥18 years and ≤80 years, able to comprehend and sign an informed consent form;\n2. Diagnosed with pancreatic adenocarcinoma confirmed histologically or cytologically;\n3. Evaluated as unresectable LAPC or metastatic pancreatic cancer with lymph node metastasis only, as determined by the investigator; or having contraindications to surgery, or refusing surgical resection;\n4. ECOG performance status score ≤1;\n5. Expected survival ≥3 months;\n6. According to RECIST v1.1 criteria, there is only one measurable lesion in the pancreas confirmed by imaging, and the lesion has the shortest axis diameter ≥2.0 cm, the longest axis diameter ≤6.0 cm (based on baseline imaging);\n7. Adequate normal organ and marrow function as defined below: (1) Renal function: serum creatinine ≤1.5×ULN, or creatinine clearance ≥60 mL\u002Fmin (calculated by the Cockcroft-Gault formula); (2) Liver function: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3×ULN; serum total bilirubin ≤1.5×ULN; (3) Bone marrow function \\[\\[no blood transfusion or granulocyte colony-stimulating factor (G-CSF), human thrombopoietin (TPO), or TPO receptor agonist treatment within 14 days prior to signing informed consent\\]: neutrophils ≥1.5×10\\^9\u002FL, hemoglobin ≥90 g\u002FL, platelets ≥100×10\\^9\u002FL; (4) Coagulation function: International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n8. Female and male participants of reproductive age must voluntarily agree to practice strict and effective contraception after signing the informed consent form, during the study period, and within 12 months after administration of the investigational drug. Males are prohibited from donating sperm during this period. Female participants of reproductive age must have a negative pregnancy test result during the screening period and within 24 hours before administration of the investigational drug.\n\nExclusion Criteria:\n\n1. Allergic to the investigational drug NRT6008 injection itself or any of its components;\n2. Contraindications to any of the three optional systemic chemotherapy regimens in this study judged by investigators;\n3. Previous anti-tumor treatments for pancreatic cancer, including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. Except for discontinuation of traditional chinese medicine or herbal medicine for at least 7 days prior to the screening period;\n4. Contraindications to anesthesia;\n5. History of any other malignant tumors within 5 years before receiving investigational drug treatment, except for cases of cured non-melanoma skin cancer, cervical carcinoma in situ, or basal cell carcinoma of the skin, Stage I Grade 1 endometrial carcinoma, or thyroid cancer;\n6. Presence or suspected presence of distant metastases according to imaging;\n7. Pregnant or lactating females;\n8. Participants assessed by the investigators to be at high risk or had difficulty in operation for EUS-FNI procedures;\n9. Evidence of radiographic invasion into stomach, duodenum or peritoneum;\n10. Participants with chronic diseases that are actively treated but not well controlled, such as primary hypertension, diabetes, etc.;\n11. Within 6 months prior to the the first administration of chemotherapy, occurrence of acute pancreatitis, severe gastrointestinal bleeding, severe cardiovascular diseases (including but not limited to stroke, unstable angina), or occurrence of acute infections requiring systemic treatment within 2 weeks before the screening period;\n12. Participated in other interventional clinical trials within 1 month prior to the first administration of chemotherapy;\n13. Positive for human immunodeficiency virus (HIV) antibodies;\n14. Positive for hepatitis B virus (HBV) surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb), HBV DNA testing required, participants with HBV-DNA levels below the lower limit of the reference range or \\\u003C 500 IU\u002FmL will be eligible for inclusion in this study (use of antiviral drugs during the study period is required);\n15. Positive for hepatitis C virus (HCV) antibodies, HCV RNA testing required, participants with negative HCV RNA results will be eligible for inclusion in this study;\n16. Participants with syphilis infection or active tuberculosis;\n17. Other reasons deemed unsuitable for participation in this trial by the investigators.","ALL","18 Years","80 Years",{"count":20,"type":21},58,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study.",[27,28,29],"Unresectable Pancreatic Cancer","Advanced Pancreatic Cancer","Lymph Node Metastases",[31,32,33,34],"Yttrium-90","Endoscopic ultrasound-guided fine-needle injection","Locally Advanced Pancreatic Carcinoma","Advanced Pancreatic Cancer with Lymph Node Metastases","RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-10","ACTUAL",{"date":41,"type":39},"2024-01-09",{"date":43,"type":21},"2028-06",{"name":45,"class":46},"Chengdu New Radiomedicine Technology Co. LTD.","INDUSTRY",6,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100603617","phase-3-a-study-comparing-mrg004a-plus-best-supportive-care-versus-placebo-and-best-supportive-care-in-the-treatment-of-patients-with-advanced-pancreatic-cancer-100603617","NCT07138846","A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","A Randomized, Double-blind, Multi-center, Phase III Study of MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Willing to sign the informed consent form and follow the requirements specified in the protocol.\n* Patients with histologically and cytologically confirmed locally advanced or metastatic pancreatic cancer, including adenocarcinoma, who have failed at least prior systemic therapies including gemcitabine and fluorouracil.\n* Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n* The score of ECOG for performance status is 0 to 2.\n* Organ functions and coagulation function must meet the basic requirements.\n* Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.\n\nExclusion Criteria:\n\n* History of other primary malignant tumors\n* Active metastasis to brain or meninges\n* Active acute or chronic inflammatory skin disease, history of Steven-Johnson syndromes\n* History of active or chronic corneal and conjunctival diseases, or other clinically significant ocular diseases that affect the ophthalmic monitoring of the investigational drug\n* Received certain anti-tumor therapies or strong CYP3A4 inhibitors and have not complete the wash-out period, or have not fully recovered from major surgery\n* AEs due to prior anti-tumor therapy(ies) that have not resolved to ≤Grade 1 per CTCAE v5.0\n* Presence of ≥Grade 2 peripheral neuropathy per CTCAE v5.0\n* Poorly controlled pleural and peritoneal effusion or pericardial effusion\n* Severe cardiac dysfunction within 6 months before enrollment\n* History of ventricular tachycardia, or torsade des pointes\n* Uncontrolled or poorly controlled hypertension\n* Compression fractures of the spine that have not been treated with surgery and\u002For radiation therapy, or have not been stable within 2 weeks before randomization\n* Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of study drug.\n* Patients with high risk of bleeding per investigator's judgement.\n* Patients who have active infection including but not limited to hepatitis B, hepatitis C, AIDS, or syphilis.\n* Active uncontrolled bacterial, viral, fungal, rickettsial, or parasitic infection.\n* Moderate to severe dyspnea at rest, severe primary lung disease, interstitial lung disease, or pneumonia.\n* Uncontrolled pain due to cancer\n* Active or history of autoimmune disease that requiring systemic hormone therapy\n* History of hypersensitivity to any component of the investigational product.\n* Other situations that are not suitable to participate a clinical trial per investigator's judgement",{"count":56,"type":21},231,[58],"PHASE3","This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.",[28],[62,63,64,65],"MRG004A","Best Supportive Care","Placebo Controlled","Pancreatic Cancer","NOT_YET_RECRUITING","2026-05-12",{"date":69,"type":39},"2026-05-15",{"date":71,"type":21},"2027-01",{"date":73,"type":21},"2027-06",{"name":75,"class":46},"Lepu Biopharma Co., Ltd.",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":47},"100638502","phase-2-a-clinical-study-evaluating-a-new-treatment-strategy-for-patients-with-advanced-pancreatic-cancer-who-have-not-received-prior-treatment-for-advanced-disease-100638502","NCT07578337","A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.","A Randomized Phase II Study of Priming Treatment With the Hedgehog Inhibitor NLM-001 Prior to Gemcitabine\u002FNab-Paclitaxel (GNab-P) plusBotensilimab and Balstilimab (Bot\u002FBal) Versus GNab-P in Patients With Previously Untreated Advanced Pancreatic Cancer (NUMANTIA-2)","NUMANTIA-2","Inclusion Criteria:\n\n1. Investigators must ensure that patients are able to understand the requirements of the study and provide informed consent.\n2. Age ≥18 years.\n3. Histological or cytological diagnosis of pancreatic adenocarcinoma.\n4. Stage IV disease.\n5. No prior treatment for advanced disease. Patients who have received chemotherapy for localized disease are eligible if they progress within six months from the last chemotherapy treatment.\n6. Measurable disease per iRECIST 1.1 as determined by the investigator.\n7. ECOG (Eastern Cooperative Oncology Group) PS 0-1.\n8. Sufficient hematopoietic, renal and liver function as defined as:\n\n   * Neutrophil count ≥ 1.5 x 10\\^9 \u002F L\n   * Platelet count ≥ 100 x 10\\^9 \u002F L\n   * Bilirubin ≤ 1.5 x ULN (upper limit of normal)\n   * AST and \u002F or ALT ≤2.5 x ULN or ≤5 for patients with liver disease\n   * Serum creatinine ≤ 1.5 x ULN\n9. Tumor lesion amenable to safe repeated tumor biopsy.\n10. Women of child-bearing age and men who wish to participate in the study must agree to use appropriate contraceptive methods from the signing of informed consent until 6 months for women and 3 months for men after discontinuation of the study drug o Adequate contraception includes abstinence, oral contraceptives, transdermal patches, and injections that prolong release of a progestogen (starting at least 4 weeks prior to the administration of the investigational drug), condom or female condom (diaphragm or condom \u002F vaginal) plus spermicide, intrauterine device (IUD), implant or a vaginal ring (placed at least 4 weeks prior to administration of investigational drug) or male partner sterilization (vasectomy with documentation of azoospermia) before the inclusion of the woman in the trial if the male is the only sex partner of the woman (see appendix G).\n\nExclusion Criteria:\n\n1. Active or uncontrolled infectious disease or serious medical condition that may interfere with the patient's eligibility or treatment.\n2. History of psychiatric condition that would compromise the patient's ability to understand or comply with the requirements of the protocol, or the ability to provide informed consent.\n3. Concurrent antineoplastic therapy.\n4. Prior chemotherapy or chemo-radiation therapy for advanced pancreatic cancer.\n5. Prior anti-PD-(L)1 or anti-CTLA-4 as prior therapy(ies).\n6. Pregnant or lactating women.\n7. History of allergic reactions attributed to compounds of similar chemical structure or similar biological study drug composition.\n8. History of life-threatening serious adverse events to Gemcitabine or Nab-Paclitaxel.\n9. Patients requiring or being treated with potent CYP3A4 inhibitors and inducers.\n10. Other active malignancies undergoing or requiring systemic treatment.\n11. History of interstitial lung disease.\n12. Subjects with history or presence of a known clotting disorder or difficulty achieving haemostasis will be excluded.\n13. Primary or secondary immunodeficiency, including immunosuppressive disease or autoimmune disease (including autoimmune endocrinopathies).\n\n    Note: Subjects with type 1 diabetes, vitiligo, psoriasis, hypo-, or hyperthyroid disease not requiring immunosuppressive treatment are eligible. Subjects with Type 2 diabetes mellitus are allowed.\n14. Subjects with a known history of human immunodeficiency virus 1 and 2, human T lymphotropic virus 1.\n15. Prior treatment with anticancer therapies, immunosuppressive agents, corticosteroids, radiation, investigational drugs or vaccines within the following time intervals before the first dose of study treatment (C1D1):\n\n    (i) Cytotoxic chemotherapy: within 3 weeks prior to C1D1. (ii) Monoclonal antibodies, antibody-drug conjugates or radioimmunoconjugates: within 4 weeks or 5 half-lives, whichever is shorter.\n\n    (iii) Small-molecule targeted therapies, including tyrosine kinase inhibitors: within 2 weeks or 5 half-lives, whichever is shorter.\n\n    (iv) Any other anti-neoplastic therapy (including experimental agents): within 3 weeks, except:\n    * Investigational drugs or devices must not have been administered within 21 days or 5 half-lives (whichever is longer).\n    * For investigational agents with long half-lives (\\>5 days), earlier enrolment requires approval by the medical monitor.\n\n      (v) Radiotherapy: - A 1-week washout is permitted for palliative radiation to non-CNS lesions, with medical monitor approval.\n    * Patients must not have experienced radiation pneumonitis or be receiving chronic corticosteroids for this condition.\n\n    (vi) Corticosteroids: - No systemic corticosteroids within 7 days, except:\n    * inhaled or topical corticosteroids,\n    * corticosteroid premedication for contrast allergy,\n    * physiologic replacement doses, with medical monitor approval. (vii) Immunosuppressive therapies: - No immunosuppressive treatment within 7 days, except for the permitted corticosteroid uses listed above.\n\n    (viii) SARS-CoV-2 vaccination:\n    * No COVID-19 vaccine within 7 days before randomization.\n    * When feasible, multi-dose vaccine series should be completed prior to randomization.\n16. Has not recovered to grade ≤1 from toxic effects of prior therapy and\u002For complications from prior surgical intervention before starting therapy.\n\n    Note: Subjects with grade ≤2 neuropathy and alopecia are an exception and may enroll.\n17. History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful.\n18. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident\u002Fstroke or myocardial infarction within 6 months of study enrollment, unstable angina, congestive heart failure (New York Heart Association class ≥ III), or serious uncontrolled cardiac arrhythmia requiring medication.\n\n    a. QTcF (QT interval corrected using Fridericia's formula) of \\> 480 ms.\n19. Concurrent participation in other investigational drug trials.\n20. Known central nervous system (CNS) involvement as follows:\n\n    * Untreated CNS metastases.\n    * Leptomeningeal metastases. Note: Patients may be eligible if CNS metastases have been treated and patients have neurologically returned to baseline (except for residual signs and symptoms related to the CNS treatment).\n21. Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Participants who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA for at least 6 months prior to study enrollment are eligible. Serological testing for HBV at screening is not required.\n22. Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Participants on or who have received antiretroviral therapy are eligible provided they are virus-free by PCR for at least 6 months prior to study enrollment. Serological testing for HCV at screening is not required.",{"count":86,"type":21},40,[88],"PHASE2","Phase II, open label, randomized multicenter study to evaluate efficacy and safety of study treatment in previously untreated patients with advanced pancreatic cancer. Patients will receive study treatment for a maximum of 24 months or until progression disease or until unacceptable toxicity. In the experimental arm, patients who discontinue chemotherapy for reasons other than disease progression may continue receiving the remaining study drugs (NLM-001, botensilimab and balstilimab) up to a maximum of 24 months, according to schedule.",[91,28],"Untreated",[93,94,95],"Pancreatic cancer","Cancer","NLM-001","2026-05-11",{"date":98,"type":39},"2026-05-13",{"date":100,"type":21},"2026-07-15",{"date":102,"type":21},"2029-02-28",{"name":104,"class":46},"Nelum Corp",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":76},"100468487","profiling-program-of-advancedmetastatic-pancreatic-cancer-patients-100468487","NCT05380414","Profiling Program of Advanced\u002FMetastatic Pancreatic Cancer Patients","A Single-center, Prospective Profiling Program of Advanced\u002FMetastatic Pancreatic Cancer Patients","Inclusion Criteria:\n\n* Male or female patient \\> 18 years\n* metastatic or advanced PDAC\n* Patient pretreated with no more than one prior systemic chemotherapy for metastatic\u002Fadvanced disease (radiotherapy is not counted as a line of therapy).\n* Availability of an archival representative FFPE tumor sample from primary tumor (surgery or diagnostic biopsy) and\u002For from metastatic lesion if metastatic disease at initial diagnosis with associated pathology report from an archival tumor block.\n* Life expectancy \\> 3 months\n* PS score 0 or 1.\n\nExclusion Criteria:\n\n* Curative therapy available\n* Any condition contraindicated with blood sampling procedures required by the protocol.\n* Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer.\n* Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.",{"count":113,"type":21},750,[115],"NA","The proposal is to implement a molecular screening program for advanced\u002Fmetastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patients for rationale personalized medicine with targeted agents and\u002For combination involving a chemotherapy backbone.",[118,28],"Metastatic Pancreatic Cancer",[120,121,122],"Molecular screening","Genomic profiles","Transcriptomic profiles","2026-03-26",{"date":125,"type":39},"2026-03-31",{"date":127,"type":39},"2022-07-01",{"date":129,"type":21},"2027-09-01",{"name":131,"class":132},"Centre Leon Berard","OTHER",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100579223","phase-1-clinical-study-evaluating-the-safety-tolerability-and-preliminary-efficacy-of-lm-108--penpulimabchemotherapy-in-advanced-solid-tumors---cohort-c-100579223","NCT06821503","Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","An Open Label Phase Ib\u002FII Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab Plus Chemotherapy in Patients With Advanced Solid Tumors - Cohort C","Inclusion Criteria:\n\n* Age 18 or above.\n* The Eastern Cooperative Oncology Group (ECOG) physical fitness status score is 0-1 points.\n* There should be at least one measurable lesion.\n* All acute toxic reactions caused by previous anti-tumor treatments or surgical procedures have been relieved to grade 0-1 or to the levels specified in the inclusion\u002Fexclusion criteria.\n* Have sufficient organ and bone marrow function\n* Expected survival period ≥ 12 weeks\n* Infertility is defined as women who have reached menopause or have undergone bilateral oophorectomy with medical records. Male participants and female participants with fertility must agree to use one medically approved contraceptive measure during the trial period and within 6 months after the last administration of the trial drug or within 9 months after the last administration of chemotherapy drug (oxaliplatin) (whichever is later). The serum pregnancy test must be negative within 3 days before starting the study medication and not during lactation.\n* With my consent and signed informed consent form.\n* Patients with a pathological diagnosis of pancreatic cancer (ductal adenocarcinoma or adenocarcinoma) have evidence of advanced or metastatic disease that is not resectable.\n* Previously received no systemic treatment for unresectable locally advanced or metastatic pancreatic cancer.\n\nExclusion Criteria:\n\n* Known High-frequency microsatellite instability (MSI-H)\u002Fdeficient mismatch repair (dMMR).\n* There is uncontrolled or symptomatic active central nervous system metastasis, which can manifest as clinical symptoms, cerebral edema, spinal cord compression, cancerous meningitis, leptomeningeal disease, and\u002For progressive growth.\n* Within 14 days prior to enrollment, there were still uncontrollable pleural effusion and ascites despite treatment such as puncture and drainage; Pericardial effusion accompanied by clinical symptoms or moderate or above.\n* Within 14 days prior to enrollment, there is an unresolved biliary obstruction, or the clinical status has remained stable for less than 14 days after biliary stent implantation.\n* Participants' weight has decreased by more than 20% or their body mass index (BMI) is less than 18 kg\u002Fm ² within the first 2 months of enrollment.\n* Received the following treatments or medications before enrollment:\n\n  1. Prior to enrollment, received treatment with C-C chemokine Receptor 8 (CCR8) antibodies, cytotoxic T-lymphocyte associated protein-4 (CTLA-4) antibodies, or other drugs that act on Tregs.\n  2. Having undergone major surgery within 28 days prior to enrollment.\n  3. Used immunosuppressive drugs within 14 days prior to enrollment.\n  4. Vaccination with attenuated live vaccine should be administered within 28 days prior to enrollment or planned within the study period and 60 days after completion of study drug treatment.\n  5. Received anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy, or tumor embolization) within 28 days before enrollment.\n* Diagnosed with any other malignant tumor within the 5 years prior to enrollment.\n* There are any active, known or suspected autoimmune diseases present.\n* Within the first 3 months of enrollment, there have been significant clinical bleeding symptoms or clear bleeding tendencies; Arterial\u002Fvenous thrombotic events that occurred within the first 6 months of enrollment.\n* Significant vascular disease occurred within the first 6 months of enrollment.\n* Severe, unhealed, or cracked wounds, as well as active ulcers or untreated fractures.\n* There is peripheral neuropathy of grade\\>1 present.\n* Have experienced gastrointestinal perforation and\u002For gastrointestinal fistula within the 6 months prior to enrollment;\n* Within the 6 months prior to enrollment, there have been clinical signs or symptoms of intestinal obstruction and\u002For gastrointestinal obstruction.\n* Existence of interstitial lung disease, non infectious pneumonia, or uncontrolled systemic diseases.\n* Known to be allergic to the investigational drug or any of its excipients; Or have experienced severe allergic reactions to other monoclonal antibodies.\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis or co infection with hepatitis B and hepatitis C.\n* Clinical symptoms or diseases of the heart that have not been well controlled:\n* Systemic use of antibiotics for at least 7 days within the 28 days prior to enrollment, or unexplained fever\\>38.5 °C during screening\u002Fbefore first administration.\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Have participated in any other drug clinical studies within 4 weeks prior to enrollment, or have not had more than 5 half lives since the last study medication.\n* Known history of abuse or drug use of psychotropic substances.\n* There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients who the researcher deems unsuitable to participate in this study.",{"count":141,"type":21},72,[24,88],"This trial is the cohort C part of a multicenter, open label Phase Ib\u002FII clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid tumors. The dose of LM-108 combined with penpulimab, albumin paclitaxel, and gemcitabine is recommended in Phase Ib.Explore the efficacy and safety of LM-108 combined with anti-tumor therapy in patients with advanced pancreatic cancer in Phase II.",[28],"2026-03-06",{"date":147,"type":39},"2026-03-10",{"date":149,"type":39},"2025-04-11",{"date":151,"type":21},"2028-12",{"name":153,"class":46},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",16,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":76},"100593410","phase-2-recombinant-human-il-21-expressing-oncolytic-vaccinia-virus-injection-hv01-in-advanced-pancreatic-cancer-100593410","NCT07006077","Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","A Phase II Trial to Evaluate the Efficacy of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Pancreatic Tumors","Inclusion Criteria:\n\n* Signing an informed consent form.\n* Men or women aged 18 to 75 years.\n* Histologically and\u002For cytologically confirmed advanced malignant advanced pancreatic tumors refractory or failed to respond to standard therapy (including disease progression and\u002For intolerable toxicities).\n* At least one measurable lesion according to RECIST v1.1 criteria, which can be injected intratumorally either directly or with the assistance of Endoscopic ultrasound. The baseline longest diameter (shortest diameter for lymph node lesions) of the lesion targeted for injection should be more than 1.5 cm, and the lesion also meets the requirements of the relevant dosing volume.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Required baseline laboratory data include:\n\n  a) Hematology: absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL, platelet (PLT) count ≥ 75×10\\^9\u002FL, hemoglobin (Hb) ≥90 g\u002FL (without supportive therapy within 14 days prior to laboratory test); b) Liver function: serum total bilirubin (TBIL) ≤1.5×ULN (or ≤3×ULN for patients with liver metastasis); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN (or\\\u003C5×ULN for patients with primary liver cancer or liver metastasis); c) Renal function: serum creatinine (Cr) ≤1.5×ULN, and creatinine clearance (Cockcroft-Gault method) ≥45 mL\u002Fmin. For men: creatinine clearance = \\[\\[140-age(yr)\\]×weight (kg)\\]\u002F\\[0.818×creatinine (μmol\u002FL)\\]; For women: creatinine clearance = \\[\\[140-age(yr)\\]×weight (kg)×0.85\\]\u002F\\[0.818×creatinine (μmol\u002FL)\\]; d) Coagulation test: activated partial thromboplastin time (APTT) ≤1.5×ULN; international normalized ratio (INR) ≤1.5×ULN.\n* Female patients of childbearing age must have a negative serum pregnancy test. Female patients of childbearing age and male patients whose partners are of childbearing age must agree to use medically approved contraceptive measures (hormonal or barrier methods or abstinence) throughout the treatment period and also within 3 months after the last dose of the investigational drug. Male patients must also avoid sperm donation.\n\nExclusion Criteria:\n\n* Receiving any of the following anti-tumor treatments within a specified time period:\n\n  a) Systemic anti-tumor treatment, including chemotherapy, large-molecule targeted therapy, immunotherapy, and endocrine therapy within 4 weeks before first dose (within 6 weeks of dosing for nitrosourea or mitomycin C); b) Small-molecule targeted therapy within 2 weeks before first dose or within 5 half-lives of the small-molecule targeted drug (whichever is longer); c) Traditional Chinese medicine or Chinese herbal medicine used as anti-tumor agent within 2 weeks before first dose; d) Radiotherapy (excluding palliative radiotherapy) within 2 weeks before first dose; e) Prior oncolytic virus treatment.\n* Acute toxic effects from prior treatments not resolved to Common Terminology Criteria for Adverse Events (CTCAE, v5.0) grade 1 or below, except for toxicities deemed safe by the investigator, such as alopecia.\n* Patients with clinical symptoms of central nervous system (CNS) metastasis or meningeal metastasis, or other evidence indicating that CNS or meningeal metastases are not controlled.\n* Known or suspected active autoimmune diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, and Hashimoto's thyroiditis).\n* History of severe cardiovascular and cerebrovascular diseases, including:\n\n  a) Acute coronary syndrome (including myocardial infarction, severe or unstable angina), myocarditis, congestive heart failure, cerebrovascular accidents, or other cardiovascular events of CTCAE (v5.0) grade 3 or higher within 12 months of dosing; b) Severe arrhythmia requiring clinical intervention (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), corrected QT interval (QTc) \\>450 ms for males or \\>470 ms for females, or a family history of long QT syndrome; c) New York Heart Association (NYHA) classification of class II or above, or left ventricular ejection fraction (LVEF) \\\u003C50%; d) Uncontrolled hypertension (as judged by the investigator) or hypotension despite standard treatment.\n* Any uncontrolled active infection requiring systemic anti-infective therapy (graded 2 or higher according to CTCAE v5.0), including but not limited to active tuberculosis, sepsis, bacteremia, fungemia, and viremia.\n* Any of the following infections: human immunodeficiency virus (HIV), syphilis spirochete(TP), active hepatitis C (positive HCV RNA test) or active hepatitis B (positive HBsAg and HBV DNA ≥ 2000 IU\u002FmL or ≥10\\^4 copies\u002FmL).\n* Use of immunomodulatory drugs within 2 weeks of dosing, including but not limited to thymosin, interleukin, interferon.\n* Pregnant or lactating women.","75 Years",{"count":164,"type":21},12,[88],"The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.",[28],[169,170,171,172],"phase Ⅱ","vaccinia virus","IL-21","Pancreatic Tumors","2026-02-25",{"date":175,"type":39},"2026-02-27",{"date":177,"type":39},"2025-05-29",{"date":179,"type":21},"2029-03-05",{"name":181,"class":46},"Hangzhou Converd Co., Ltd.",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":201,"locationsCount":76},"100624946","early-phase-1-exploratory-clinical-study-of-claudin182-targeted-activated-dc-and-car-t-therapy-in-advanced-pancreatic-cancer-100624946","NCT07416240","Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.","Exploratory Clinical Study of Combined Claudin18.2-Targeted Activated DC and CAR-T Therapy in Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years, upper limit ≤ 80 years, gender not limited;\n2. Participants must have a histologically or cytologically confirmed diagnosis of advanced pancreatic cancer, with at least one measurable lesion meeting RECIST v1.1 criteria (i.e., a target lesion with a longest diameter ≥10 mm on spiral CT scan, or a lymph node with a short axis ≥15 mm).\n3. Tumor tissue positive for Claudin 18.2 by immunohistochemical detection (expression intensity ≥ 2+; expression range ≥ 50%);\n4. Meeting the indications for PBMC collection and having no other contraindications for cell collection;\n5. Failure of standard second-line treatment or lack of a standard treatment regimen; or signing a refusal to undergo chemotherapy.\n6. ECOG score: 0-1;\n7. Life expectancy: ≥ 3 months;\n8. Toxic reactions from previous chemotherapy and other anti-tumor treatments must be resolved through a washout period (except for residual hair loss), ensuring that all functional parameters meet the inclusion criteria;\n9. Sufficient organ function, including:\n\n   1. Sufficient immune function, i.e., absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹\u002FL, absolute neutrophil count (ANC) ≥ 1.0 × 10⁹\u002FL, monocyte count ≥ 0.1 × 10⁹\u002FL.\n   2. Sufficient hematopoietic function, i.e., platelet count ≥ 75 × 10⁹\u002FL, hemoglobin ≥ 90 g\u002FL. Patients must not have received blood transfusions or treatments such as granulocyte colony-stimulating factor, thrombopoietin, or erythropoietin within 14 days prior to the complete blood count examination. c) Sufficient liver function, i.e., total bilirubin (TBIL) \\\u003C 2 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 2.5 × ULN.\n\n   d) Sufficient kidney function, i.e., creatinine (Cr) ≤ 1.5 × ULN. e) Sufficient coagulation function, i.e., prothrombin time (PT) or activated partial thromboplastin time (APTT) \\\u003C 1.5 × ULN, and international normalized ratio (INR) \\\u003C 1.5.\n10. Individuals of fertility must be willing to use contraception;\n11. Sufficient understanding and willingness to sign an informed consent form;\n12. Willingness to comply with visit schedules, medication plans, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n1. Emergency oncological conditions requiring immediate treatment, such as malignant pericardial effusion or tamponade, superior vena cava obstruction syndrome, spinal cord compression, etc.\n2. Significant cardiovascular disease, such as:\n\n   1. • A confirmed cardiovascular event within the past 6 months, such as myocardial infarction, angina pectoris, heart failure, severe arrhythmia, or previous angioplasty, stent implantation, or coronary artery bypass grafting;\n   2. • Clinically significant QT interval prolongation (QTcF \\> 470ms for women or QTcF \\> 450ms for men).\n3. Clinically significant bleeding tendency or coagulation disorders, such as hemophilia;\n4. HIV infection, syphilis infection, hepatitis B infection, or hepatitis C infection.\n5. History of involuntary custody due to mental illness or other mental illness deemed unsuitable for treatment by the treating physician;\n6. Accompanied by other autoimmune diseases, or long-term use of immunosuppressants or steroids;\n7. Poor patient compliance as assessed by the investigator;\n8. Previous treatment with any target CAR-T within 3 months prior to this CAR-T treatment;\n9. Uncontrollable active bacterial or fungal infections;\n10. Other conditions deemed necessary to be ruled out by the physician.",{"count":190,"type":21},10,[192],"EARLY_PHASE1","This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer.\n\nThis combination therapy activates dendritic cells (DCs) to precisely target the tumor site, reshaping the tumor immune microenvironment, breaking down the immunosuppressive barrier, and allowing CAR-T cells to penetrate deeper into the tumor more efficiently, precisely and persistently killing cancer cells.",[28],"2026-02-10",{"date":197,"type":39},"2026-02-18",{"date":197,"type":21},{"date":200,"type":21},"2028-08-18",{"name":202,"class":132},"Hainan Cancer Hospital",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":209,"targetDuration":210,"studyType":211,"phases":4,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":76},"100594951","a-real-world-study-of-liposomal-irinotecan-onivyde-based-therapy-in-patients-with-locally-advancedmetastatic-pancreatic-cancer-in-china-100594951","NCT07026123","A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced\u002FMetastatic Pancreatic Cancer in China","Inclusion Criteria of the experimental group:\n\n* Age ≥ 18 years old.\n* Patients with locally advanced or metastatic PDAC diagnosed by pathology.\n* Patients who received at least one cycle of Nal-IRI (Onivyde®）+ 5-FU\u002FLV treatment.\n* Patients who have progressed in treatment with gemcitabine or gemcitabine containing regimens in the past.\n* The patient voluntarily participates in the study and signs an informed consent form.\n\nInclusion Criteria of the control group:\n\n* Age ≥ 18 years old.\n* Patients with locally advanced or metastatic PDAC diagnosed by pathology.\n* Not received Nal IRI (Onivyde®)+ 5-FU\u002FLV treatment in the past.\n\nExclusion Criteria:\n\n* Confirm pregnant or lactating women.\n* The patient's clinical data is not available.\n* The researchers determined that they were not suitable for inclusion in the study due to other circumstances.",{"count":86,"type":21},"2 Years","OBSERVATIONAL","This study is designed to evaluate the real world efficacy and safety of the liposomal irinotecan (Onivyde®)-based treatment scheme in Chinese patients with locally advanced or metastatic pancreatic cancer, and to compare the efficacy with that of the whole pancreatic cancer population who did not receive relevant treatment.",[28],[65,215,216,217],"chemotherapy","liposomal irinotecan","real world research","2025-06-10",{"date":220,"type":39},"2025-06-18",{"date":222,"type":21},"2025-07-01",{"date":224,"type":21},"2027-07-31",{"name":226,"class":132},"RenJi Hospital",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":4},"100553965","phase-3-a-study-of-docetaxel-for-injection-albumin-bound-in-patients-with-advanced-pancreatic-cancer-100553965","NCT06492941","A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","A Randomized, Double-blind, Multicenter Phase Ⅲ Clinical Study of Docetaxel for Injection (Albumin Bound) Combined With Best Supportive Care Versus Placebo Plus Best Supportive Care in Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* 1\\. Patients aged ≥18 years (subject to the date when the informed consent form is signed) and voluntarily signed the informed consent form.\n* 2\\. Histologically or cytologically confirmed diagnosis of pancreatic cancer (including adenosquamous carcinoma).\n* 3\\. Patients who have got disease progression or toxic intolerance after previous standard treatment (gemcitabine based and fluorouracil based therapy).\n* 4\\. At least one evaluable lesion according to RECIST 1.1 .\n* 5\\. Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n* 6\\. Patients with fine organ function (no medical supportive treatments such as blood component transfusion, growth factors within 2 weeks before taking the relevant inspections):\n\n  1. ANC≥1.5×10\\^9\u002FL；\n  2. Hb≥90 g\u002FL；\n  3. PLT≥100×10\\^9\u002FL；\n  4. ALB≥30 g\u002FL；\n  5. CR≤1.5× ULN and creatinine clearance≥40 mL\u002Fmin（Cockcroft-Gault）；\n  6. Total bilirubin≤1.5 × ULN(≤ 2 × ULN for patients with obstructive jaundice, ≤3 × ULN for patients with Gilbert's syndrome)；\n  7. ALT and AST ≤ 3× ULN (≤5× ULN for patients with liver metastasis)；\n  8. ALP≤2.5× ULN；\n  9. PT、INR≤1.5×ULN。\n* 7\\. The patient must agree to take adequate contraception from signing of ICF through 6 months after last dose, women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose of the investigational drug.\n\nExclusion Criteria:\n\n* 1\\. Patients who have a history of severe allergy to any excipients of the investigational drug or taxanes，or known allergy and\u002For contraindications to glucocorticoids (including but not limited to active digestive tract ulcers, severe hypertension, severe hypokalemia, glaucoma, etc.).\n* 2\\. Patients with partial or complete intestinal obstruction or complete biliary obstruction that cannot be relieved by active treatment.\n* 3\\. Previous history of inflammatory bowel disease, chronic diarrhea, and gastrointestinal bleeding.\n* 4\\. Patients who had a history of other active malignant tumors within 2 years before the first dose of the investigational drug, except for the study disease pancreatic cancer and curable cancer that had been cured (such as basal cell or squamous cell skin cancer, superficial bladder cancer, cervical cancer or breast cancer in situ that had been excised).\n* 5\\. Patients with active hepatitis B (HBsAg and\u002For HBcAb positive but HBV DNA \\\u003C 2000 IU\u002FmL can be included), active hepatitis C (HCV antibody positive but HCV RNA negative can be included), and HIV antibody positive.\n* 6\\. Adverse reactions from the previous anti-tumor treatment have not yet recovered to ≤ level 1 based on CTCAE 5.0 (except for alopecia, hyperpigmentation, or other toxicity without safety risk judged by the investigator).\n* 7\\. Patients with a history of severe cardiovascular disease, including but not limited to:：\n\n  1. Severe heart rhythm or conduction abnormalities, including but not limited to ventricular arrhythmia requiring clinical intervention and third degree atrioventricular block within 6 months before the first dose of the investigational drug；\n  2. History of myocardial infarction, unstable angina pectoris, angioplasty and coronary artery bypass surgery within 6 months before the first dose of the investigational drug;；\n  3. Heart failure with New York Heart Association (NYHA) Classification of Class Ш and above；\n  4. Long QTc syndrome or QTc \\> 480 msec；\n  5. Poorly controlled hypertension (Systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg at screening period).\n* 8\\. Patients with uncontrolled serous cavity effusion requiring frequent drainage or medical intervention (e.g., pleural effusion, abdominal effusion, pericardial effusion, etc., additional intervention was needed within 2 weeks after intervention, excluding exfoliative cytology testing of the exudate) within 2 weeks before the first dose of the investigational drug.\n* 9\\. Patients with severe or active infections (including tuberculous infections) that require systemic antibacterial, antifungal, or antiviral therapy within 14 days before the first dose of the investigational drug, antiviral therapy for patients with viral hepatitis is permitted.\n* 10\\. Received any anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) and any clinical trial intervention within 4 weeks prior to the first use of the investigational drug or within 5 half-lives of the most recently used anti-tumor drug (whichever is shorter), and used traditional Chinese medicine or proprietary Chinese medicine with anti-tumor indications within 14 days before the first use of the investigational drug.\n* 11\\. Patients who have used potent inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of the investigational drug.\n* 12\\. Patients who have undergone major surgery within 4 weeks before the first dose of the investigational drug and had not recovered sufficiently, or who need to undergo major surgery during the study.\n* 13\\. Pregnant or nursing women.\n* 14\\. Patients who is participating in another clinical study simultaneously unless it is an observational (non-interventional) clinical study or within the follow-up period of an interventional study.\n* 15\\. Other situations that the investigator considers not suitable for participating in the clinical study, including but not limited to: the patient is complicated by severe or uncontrolled medical conditions, which will increase the safety risk, interfere with the interpretation of study results or affect the study compliance.",{"count":235,"type":21},142,[58],"This study is a randomized, double-blind, multicenter, phase Ⅲ clinical study to compare the clinical efficacy and safety of Docetaxel for Injection (Albumin Bound) in combination with best supportive care versus placebo in combination with best supportive care in participants with pancreatic cancer who have received gemcitabine-containing and fluorouracil-containing regimens.",[28],"2024-07-02",{"date":241,"type":39},"2024-07-09",{"date":243,"type":21},"2024-08-12",{"date":245,"type":21},"2026-11-21",{"name":247,"class":46},"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":76},"100541444","phase-2-a-phase-ii-study-of-surufatinib-combined-with-camrelizumab-and-mfolfox6-as-second-line-treatment-for-advanced-prad-100541444","NCT06329947","A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD","Inclusion Criteria:\n\n1. Have full understanding of this study and voluntarily sign the informed consent form;\n2. Male and Female aged between 18 and 75 years are eligible;\n3. Histologically or cytologically confirmed metastatic pancreatic cancer;\n4. Patients who have previously failed first-line gemcitabine-based chemotherapy or have disease progression\u002Frecurrence during previous neoadjuvant\u002Fadjuvant treatment or within 6 months after the end of treatment are considered to have failed first-line systemic chemotherapy; neoadjuvant\u002Fadjuvant treatment plan Also gemcitabine-based chemotherapy;\n5. Presence of at least one measurable target lesion for further evaluation according to RECIST criteria;\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n7. Predicted survival ≥12 weeks;\n8. Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 6 months after the last dose of study drug.\n\nExclusion Criteria:\n\n1. Participated in other anti-tumor drug clinical trials within 28 days;\n2. Have previously received any anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody or acted on T cell costimulation or checkpoints Treatment with any other antibodies of the pathway (such as OX40, CD137, etc.);\n3. Have previously received anti-vascular endothelial growth factor\u002Fvascular endothelial growth factor receptor (VEGF\u002FVEGFR) targeted drug treatment;\n4. Those who are known to be allergic to any of the drugs in the study;\n5. Brain metastasis accompanied by symptoms or symptom control time \\\u003C2 months;\n6. The subject has suffered from other malignant tumors in the past or at the same time within 5 years (except cured basal cell carcinoma of the skin and cervical cancer in situ);\n7. Insufficient bone marrow hematopoietic function (without blood transfusion within 14 days):\n\n   1. Absolute neutrophil count (ANC) \\\u003C1.5×109\u002FL;\n   2. Platelets \\\u003C100×109\u002FL;\n   3. Hemoglobin \\\u003C8g\u002FdL.\n8. Liver abnormalities:\n\n   1. When there is no liver metastasis, ALT, AST or ALP\\>2.5×the upper limit of the normal reference range (ULN); when there is liver metastasis, ALT, AST or ALP\\>5×ULN;\n   2. Serum total bilirubin \\>1.5×ULN (Gilber syndrome \\>3×ULN);\n   3. Decompensated cirrhosis (Child-Pugh liver function grade B or C);\n   4. Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA copy number ≥2000IU\u002FmL (those who are HBsAg positive and hepatitis B virus DNA copy number \\\u003C2000IU\u002FmL need to receive at least 2 weeks of anti-HBV treatment before taking the first dose) ;\n   5. Hepatitis C virus (HCV) antibody positive and HCVRNA test positive.\n9. Kidney abnormalities:\n\n   1. Serum creatinine\\>1.5×ULN;\n   2. Routine urine test shows urine protein ≥++, and the 24-hour urine protein quantification is confirmed to be \\>1.0g;\n   3. Renal failure requiring hemodialysis or peritoneal dialysis;\n   4. Past history of nephrotic syndrome.；",{"count":255,"type":21},37,[88],"To preliminarily evaluate whether there is a survival benefit of surufatinib combined with camrelizumab and mFOLFOX6 as the second-line treatment for advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer",[28],"2024-05-06",{"date":261,"type":39},"2024-05-08",{"date":263,"type":21},"2024-05-22",{"date":265,"type":21},"2026-09-30",{"name":267,"class":132},"Rui-hua Xu, MD, PhD",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":76},"100522143","phase-2-olaparib-in-palb2-advanced-pancreatic-cancer-100522143","NCT06078787","Olaparib in PALB2 Advanced Pancreatic Cancer","A Phase II Multicentric Study of Olaparib in PALB2-related Advanced Pancreatic Cancer (PALBOLA)","PALBOLA","Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed pancreatic adenocarcinoma\n* Has advanced (unresectable or metastatic) pancreatic cancer by American Joint Committee on Cancer 8th Edition\n* Has documented mutation in PALB2 gene (germline or somatic) that is predicted to be deleterious or suspected deleterious.\n* Has at least one lesion (measurable) that can be accurately assessed at baseline by CT scan (or MRI, if the subject is allergic to CT contrast media) and is suitable for repeated assessment according to RECIST Version 1.1 criteria.\n* Has a life expectancy ≥16 weeks.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1, as assessed within 3 days of the treatment initiation.\n* Has received at least one systemic treatment for advanced disease (locally advanced or metastatic disease).\n* Has adequate organ function as defined in Table 2; all screening laboratory tests should be performed within 10 days prior to initiation of study intervention.\n* Is male or female, who is at least 18 years of age at the time of signing the informed consent.\n\nMale Participants Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\n* A male participant must agree to use contraception ad detailed in Appendix D of this protocol during the treatment period and for at least 3 months following the last dose of Olaparib when having sexual intercourse with pregnant woman or with a WOPBP. Female partners of male patients should also use a highly effective form of contraception (\\[see appendix D for acceptable methods\\]) if they are of childbearing potential Male patients should not donate sperm throughout the period of taking olaparib and for 3 months following the last dose of olaparib.\n\nFemale Participants Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\n* 11\\. A female participant is eligible to participate if she is not pregnant\\* (Appendix D), not breastfeeding and at least 1 of the following conditions applies:\n\n  1. Not a WOCBP as defined in Appendix D\n\n     OR\n  2. A WOCBP who agrees to follow the contraceptive guidance in Appendix D during treatment period and for least one month after the last dose of study intervention.\n\nPostmenopausal is defined as:\n\n* Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments\n* Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50\n* radiation-induced oophorectomy with last menses \\>1 year ago\n* chemotherapy-induced menopause with \\>1 year interval since last menses\n* surgical sterilisation (bilateral oophorectomy or hysterectomy)\n\n  * evidence of non-childbearing status for women of childbearing potential is defined with negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1 (within 24 hours) and before every cycles.\n\nInformed Consent\n\n* Has (or legally acceptable representative if applicable) provided written informed consent for the study. The participant may also provide consent\u002Fassent for future biomedical research. However, the participant may participate in the main trial without participating in the FBR.\n\nExclusion Criteria:\n\n* Has a known additional malignancy that is progressing or requires active treatment. Other malignancy unless curatively treated with no evidence of disease for ≥5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma.\n* Has myelodysplastic syndrome\u002Facute myeloid leukaemia or features suggestive of MDS\u002FAML.\n* 3\\. Patients with symptomatic uncontrolled brain metastases and\u002For carcinomatous meningitis. Subject with previously treated brain metastasis may participate proved they are stable (without evidence of progression by imaging for at leat four weeks prior to the first dose of trial treatment and any neurological symptoms have returned to baseline), no evidence of new or enlarging brain metastases. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.\n* 4\\. Has a documented weigh loss \\> 10% from baseline during screening and\u002For decline in ECOG PS to \\>1 between visit and within 73 hours prior to first dose of therapy.\n* Has an active infection requiring systemic therapy.\n* Has a known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Persistent toxicities (\\>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia. Patients previously treated with Oxaliplatinum who experienced a ≤ G2 neuropathy can be included after consultation with the study physician\n* Patients considered at poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.\n* Is unable to swallow orally administered medication or patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n* Is a immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).\n* Has a known active hepatitis (i.e. Hepatitis B or C).\n\n  * Active hepatitis B virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible.\n  * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n\nPrior\u002Fconcomitant therapy\n\n* Any previous treatment with PARP inhibitor, including Olaparib.\n* Has prior systemic chemotherapy, targeted small molecule therapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment.\n* Has received prior therapy with an anti-monoclonal antibody within 4 weeks or who has not recovered (i.e. \\\u003C= G1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n* 15\\. Bone as only site of metastatic disease from pancreatic cancer (bone only disease)\n* 16\\. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\n* 17\\. Is currently receiving known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.\n* 18\\. Is currently receiving known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.\n* 19\\. Has received previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).\n* 20\\. Has received a whole blood transfusions in the last 120 days prior to entry to the study. Packed red blood cells and platelet transfusions are acceptable, if not performed within 28 days of the first dose of study intervention.\n\nPrior\u002Fconcurrent clinical study experience\n\n* 21\\. Patients that is currently participating or has participated in another clinical study with an investigational product administered in the last 4 weeks\n* 22\\. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.\n\nDiagnostic assessments\n\n* 23\\. Has resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \\>500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.\n* 24\\. Has a history or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n\nOther exclusions\n\n* Has a benign variant of PALB2 gene or variant of uncertain (or unknown) significance (VUS)\n* Has a histology other than pancreatic adenocarcinoma (for example, neuroendocrine, adenosquamous etc.)\n* Involvement in the planning and\u002For conduct of the study\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n* Is pregnant or breastfeeding,or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 30-90 days after the last dose of trial treatment.",{"count":154,"type":21},[88],"This is a Phase II, non-randomized, multicenter, unblinded open-label study of Olaparib in monotherapy in participants with advanced (locally advanced\u002Fmetastatic) PALB2-related pancreatic cancer that have progressed after at least one treatment for advanced disease.",[28,118],"2024-05-03",{"date":259,"type":39},{"date":283,"type":39},"2023-08-01",{"date":285,"type":21},"2026-08-01",{"name":287,"class":132},"Azienda Ospedaliero-Universitaria di Modena",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":309},"100524633","phase-2-a-phase-2-study-of-absk021-in-patients-with-advanced-pancreatic-cancer-100524633","NCT06111274","A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily.\n* Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology.\n* Measurable disease as defined by RECIST 1.1.\n* Without systemic treatment for pancreatic cancer.\n* ECOG physical strength score 0-2\n* Estimated survival time \\>=3 months.\n* The adequate bone marrow fuction and coagulation function\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any components of the investigational drug product.\n* Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)\u002FColony Stimulating Factor 1 Receptor (CSF-1R).\n* With Breast Cancer Gene 1\u002F2 (BRCA1\u002F2) gene mutation.\n* With a history of other malignancies within 5 years.\n* During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment.\n* With conditions that significantly affected the absorption of oral drug.\n* Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.\n* During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment.\n* Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization.\n* Previous peripheral neuropathy \\> grade 1 (Common Terminology Criteria for Adverse Events, version 5.0).\n* Diagnosed with immune deficiency or interstitial lung disease.\n* The patients were vaccinated within 4 weeks before the first treatment.\n* Participated in any drug clinical trial within 4 weeks before the first treatment.\n* Active central nervous system (CNS) metastases.\n* Impaired cardiac function or clinically significant cardiac disease.\n* Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study.\n* Known active infections from certain viruses, bacteria or parasites.\n* Patients with refractory\u002Funcontrolled ascites or pleural effusion.\n* Pregnant or lactating women.\n* Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included.",{"count":296,"type":21},82,[88],"The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are:\n\n* Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer.\n* Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer.\n\nParticipants will be asked to complete the study procedures:\n\n* Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B.\n* Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2.\n* Complete the study procedures specified in the protocol, which is guided by researchers.",[28],"2024-04-10",{"date":302,"type":39},"2024-04-11",{"date":304,"type":39},"2023-10-17",{"date":306,"type":21},"2026-12-29",{"name":308,"class":46},"Abbisko Therapeutics Co, Ltd",5,{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":76},"100509656","early-phase-1-personalized-tumor-vaccines-and-pabolizumab-in-patients-with-advanced-pancreatic-cancer-100509656","NCT05916261","Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer","Clinical Study of Personalized Tumor Vaccines mRNA-0217\u002FS001 and Pabolizumab in Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Subjects voluntarily signed written informed consent files,Able to comply with the study protocol, in the investigator's judgment\n2. Subjects must be \\>\u002F= 18 years of age at time of informed consent, regardless of gender\n3. Subjects with locally advanced, recurrent or metastatic solid tumors confirmed by histology or cytology within the past 6 months, who have failed standard treatment or are currently not suitable for standard treatment\n4. No copy number variations (CNVs) or loss of heterozygosity (Loss-of heterozygosity, LOH) were found in HLA-related genes and chromosomal regions by gene sequencing\n5. Advanced or metastatic lesions confirmed by immunohistochemistry, and cryopreserved tissues\u002Fcells, enough for WES and RNAseq sequencing, and predicted by bioinformatics analysis, at least one antigen effectively presented by self-HLA was found , such as KRAS or TP53 mutations and correspondingly presented HLA types\n6. Life expectancy ≥ 4 months\n7. Have measurable disease per RECIST 1.1 as assessed by the local site investigator\u002Fradiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions\n8. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale\n9. Have adequate organand bone marrow function,No use of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), red blood cell transfusion and platelet transfusion within 14 days before the examination.\n10. Fertile eligible patients (male and female) must agree to use reliable contraceptive methods (hormone or barrier method or abstinence) during the trial and at least 90 days after the last dose. female patients of childbearing age before the first dose A blood pregnancy test within 7 days must be negative.\n11. Subjects need to undergo virological examination: those without CMV and EBV, HIV, HBV, HCV, and syphilis infection (only in the baseline period)\n\nExclusion Criteria:\n\n1. Has had chemotherapy, hormone therapy, traditional Chinese medicine, or biological cancer(for mitomycin and nitrosoureas within 6 weeks from the first dose of the drug in this study)， prior to the first dose of study therapytherapy within 4 weeks ,Or within 5 half-lives of immunotherapy, molecular targeted therapy\n2. Subjects have undergone major surgical procedures other than the diagnosis or biopsy of the current tumor within 4 weeks before the first dose of mRNA-0217\u002FS001, or are expected to undergo major surgery during the study period\n3. Subjects have received allogeneic hematopoietic stem cell transplantation or organ transplantation in the past, or those who plan to receive organ transplantation during this study\n4. Subjects have previously received other tumor vaccines or cell therapy\n5. Brain metastases with clinical symptoms, spinal cord compression, cancerous meningitis, or other evidence that the brain and spinal cord metastases have not been controlled, and the researchers judged that they are not suitable for enrollment\n6. Other malignant tumors known to be progressing or requiring active treatment in the past 2 years (except for non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix that have been cured by surgical curative treatment)\n7. History of interstitial lung disease (ILD), pulmonary fibrosis\n8. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to a) severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular block corrected QTc interval male \\> 450 milliseconds, female \\> 470 milliseconds, b) Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months before the first administration, c) New York Heart Association (NYHA) ≥ III heart failure or left ventricular ejection fraction (LVEF) \\\u003C 50%.\n9. Other serious and\u002For uncontrollable diseases, which may affect the subject's participation in this study, include but not limited to a) a history of severe drug allergy, or is known to be allergic to any tumor vaccine and pembrolizumab formulation components or has had severe allergic reactions to other monoclonal antibodies in the past, b) A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, c) Evidence of severe or uncontrolled liver or kidney disease, d) Uncontrolled high blood pressure, diabetes, etc., e) Patients with active ulcers, gastrointestinal bleeding, f) Serious infection requiring intravenous antibiotics or hospitalization or uncontrolled active infection within 4 weeks before the first dose, g) have an active syphilis infection.\n10. Participate in other clinical trials within 4 weeks before the first dose (except for screening failure)\n11. Those who are currently receiving systemic steroids (except those who have recently or currently used inhaled steroids)\n12. Pregnant and lactating women\n13. Imaging (CT or MRI) shows that the tumor invades large blood vessels and has a tendency to hemorrhage\n14. Have clinically significant thyroid dysfunction, and the investigator judges that they are not suitable for enrollment\n15. Active pneumonia found in chest CT scan during the screening period\n16. Uncontrolled pleural effusion, pericardial effusion, or ascites that needs repeated drainage\n17. Subjects who have adverse reactions of the previous anti-tumor therapy have not recovered to NCI-CTCAE 5.0 grade evaluation ≤ grade 1 (except for hair loss)\n18. HBsAg positive and peripheral blood HBV DNA detection value is higher than the upper limit of normal, and\u002For HCV Ab positive and HCV RNA detection value is higher than the upper limit of normal\n19. Researchers believe that there are other reasons that are not suitable for participating in clinical trials",{"count":318,"type":21},54,[192],"The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217\u002FS001 vaccine encoding personalized tumor neoantigens alone\u002Fin combination with Pembrolizumab injection for the treatment of Advanced Pancreatic Cancer. The secondary objective was to observe the preliminary efficacy of mRNA-0217\u002FS001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217\u002FS001 personalized tumor vaccine.",[28],[323],"Personalized neoantigen tumor vaccine","2023-10-24",{"date":326,"type":39},"2023-10-26",{"date":328,"type":39},"2023-04-26",{"date":330,"type":21},"2026-12-30",{"name":332,"class":132},"Ruijin Hospital"]